Rice Hall James & Associates, LLC Puma Biotechnology, Inc. Transaction History

Rice Hall James & Associates, LLC

$1.69 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$2.92 - $5.83 $13,683 - $27,319	4,686 Added 3.34%	144,792 $472,000
Q1 2024 Apr 23, 2024	SELL	$4.29 - $7.4 $814,087 - $1.4 Million	-189,764 Reduced 57.53%	140,106 $742,000
Q4 2023 Feb 08, 2024	SELL	$2.23 - $4.49 $75,365 - $151,744	-33,796 Reduced 9.29%	329,870 $1.43 Million
Q3 2023 Nov 02, 2023	SELL	$2.63 - $4.09 $19,377 - $30,135	-7,368 Reduced 1.99%	363,666 $956,000
Q2 2023 Jul 24, 2023	BUY	$2.6 - $3.58 $9,196 - $12,662	3,537 Added 0.96%	371,034 $1.31 Million
Q1 2023 May 11, 2023	SELL	$2.21 - $4.82 $34,743 - $75,775	-15,721 Reduced 4.1%	367,497 $1.14 Million
Q4 2022 Jan 27, 2023	SELL	$2.12 - $5.08 $9,160 - $21,950	-4,321 Reduced 1.11%	383,218 $0
Q3 2022 Nov 01, 2022	SELL	$2.27 - $3.84 $269,056 - $455,143	-118,527 Reduced 23.42%	387,539 $918,000
Q2 2022 Aug 08, 2022	SELL	$1.64 - $3.3 $8,473 - $17,051	-5,167 Reduced 1.01%	506,066 $1.44 Million
Q1 2022 May 05, 2022	BUY	$2.13 - $3.24 $42,495 - $64,641	19,951 Added 4.06%	511,233 $1.47 Million
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $156,824 - $362,071	-55,026 Reduced 10.07%	491,282 $1.49 Million
Q3 2021 Nov 09, 2021	BUY	$6.63 - $9.39 $4,587 - $6,497	692 Added 0.13%	546,308 $3.83 Million
Q2 2021 Jul 29, 2021	SELL	$8.98 - $11.6 $540,380 - $698,041	-60,176 Reduced 9.93%	545,616 $5.01 Million
Q1 2021 May 14, 2021	BUY	$9.38 - $13.63 $8,019 - $11,653	855 Added 0.14%	605,792 $5.89 Million
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $186,268 - $290,416	23,942 Added 4.12%	604,937 $6.21 Million
Q3 2020 Nov 16, 2020	BUY	$9.5 - $11.14 $1.19 Million - $1.4 Million	125,428 Added 27.53%	580,995 $5.86 Million
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $76,514 - $144,514	-10,915 Reduced 2.34%	455,567 $4.75 Million
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $278,668 - $646,529	-44,374 Reduced 8.69%	466,482 $3.94 Million
Q4 2019 Jan 29, 2020	SELL	$6.5 - $10.73 $280,384 - $462,849	-43,136 Reduced 7.79%	510,856 $4.47 Million
Q3 2019 Oct 30, 2019	SELL	$8.75 - $12.85 $42,848 - $62,926	-4,897 Reduced 0.88%	553,992 $5.96 Million
Q2 2019 Aug 01, 2019	SELL	$12.3 - $35.76 $241,842 - $703,113	-19,662 Reduced 3.4%	558,889 $7.1 Million
Q1 2019 May 01, 2019	BUY	$20.77 - $42.37 $2.33 Million - $4.76 Million	112,241 Added 24.07%	578,551 $22.4 Million
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $4.56 Million - $10.6 Million	227,311 Added 95.11%	466,310 $9.49 Million
Q3 2018 Oct 25, 2018	BUY	$41.2 - $59.85 $2.65 Million - $3.84 Million	64,242 Added 36.76%	238,999 $11 Million
Q2 2018 Aug 02, 2018	BUY	$48.3 - $68.25 $328,101 - $463,622	6,793 Added 4.04%	174,757 $10.3 Million
Q1 2018 Apr 25, 2018	BUY	$59.7 - $99.25 $3.68 Million - $6.12 Million	61,692 Added 58.05%	167,964 $11.4 Million
Q4 2017 Jan 23, 2018	BUY	$93.85 - $132.45 $7.79 Million - $11 Million	82,953 Added 355.73%	106,272 $10.5 Million
Q3 2017 Oct 30, 2017	BUY	$72.0 - $119.75 $1.68 Million - $2.79 Million	23,319	23,319 $2.79 Million

Others Institutions Holding PBYI

# of Institutions

101

Shares Held

29M

Call Options Held

50.6K

Put Options Held

16.3K

Vanguard Group Inc Valley Forge, PA

3.64M
Shares

$10.9 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.57M
Shares

$10.7 Million
0.0% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

3.06M
Shares

$9.19 Million
0.42% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.88M
Shares

$8.64 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.97M
Shares

$5.91 Million
0.02% of portfolio

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $137M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.

Account